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Autism spectrum disorders (ASD) are a group of related neurodevelopmental syndromes with complex genetic etiology.1 We identiﬁed
a de novo chromosome 7q inversion disrupting Autism susceptibility candidate 2 (AUTS2) and Contactin Associated Protein-Like 2
(CNTNAP2) in a child with cognitive and social delay. We focused our initial analysis on CNTNAP2 based on our demonstration of dis-
ruption of Contactin 4 (CNTN4) in a patient with ASD;2 the recent ﬁnding of rare homozygous mutations in CNTNAP2 leading to intrac-
table seizures and autism;3 and in situ and biochemical analyses reported herein that conﬁrm expression in relevant brain regions and
demonstrate the presence of CNTNAP2 in the synaptic plasma membrane fraction of rat forebrain lysates. We comprehensively rese-
quenced CNTNAP2 in 635 patients and 942 controls. Among patients, we identiﬁed a total of 27 nonsynonymous changes; 13 were
rare and unique to patients and 8 of these were predicted to be deleterious by bioinformatic approaches and/or altered residues conserved
across all species. One variant at a highly conserved position, I869T, was inherited by four affected children in three unrelated families,
but was not found in 4010 control chromosomes (p ¼ 0.014). Overall, this resequencing data demonstrated a modest nonsigniﬁcant
increase in the burden of rare variants in cases versus controls. Nonethless, when viewed in light of two independent studies published
in this issue ofAJHG showing a relationship between ASD and commonCNTNAP2 alleles,4,5 the cytogenetic andmutation screening data
suggest that rare variants may also contribute to the pathophysiology of ASD, but place limits on the magnitude of this contribution.The clinical hallmarks of ASD (MIM 209850) are derange-
ments in reciprocal social interaction, abnormal develop-
ment of speech and language, and the presence of highly
restricted interests and stereotyped behaviors.6 Fundamen-
tal impairment in some but not all of these domains
deﬁnes a spectrum of conditions that includes Asperger
syndrome and Pervasive Developmental Disorder Not Oth-
erwise Speciﬁed (PDD-NOS). In the DSM-IV, rare develop-
mental disorders including Rett Syndrome and Childhood
Disintegrative Disorder6 are grouped in the same diagnos-
tic category. A majority of patients with ASD have MR in
addition to their social disability and up to one-third suf-
fer from seizures.6 Individuals with ASD also show an
increased burden of chromosomal abnormalities1 and de
novo rare copy number variants.7
Despite multiple lines of evidence suggesting a complex
genetic etiology, common ASD variants have been ex-
tremely difﬁcult to identify.1 In addition, to date there has
not been a convergence between the rare mutations identi-
ﬁed in nonsyndromic autism, such as those in the Neuroli-
gin gene family,8–13 and those genomic regions most
strongly implicated by nonparametric linkage or common
variant association studies. Difﬁculties in clarifying the ge-The Amnetic substrates of ASD likely reﬂect the combination of
marked locus and allelic heterogeneity, the absence of reli-
able biological diagnostic markers, and the likelihood that
any contributing common alleles will be found to carry
quite small increments of risk, requiring very large sample
sizes to deﬁnitively conﬁrm their contributions.1
Because of high rates of overlap between ASD, MR, and
chromosomal abnormalities, we have usedmolecular cyto-
genetic mapping of balanced rearrangements in children
with social and cognitive delays as a means of identifying
candidate genes that may harbor rare disease alleles. We
evaluated a patient with MR and a de novo inversion of
chromosome 7 (46,XY,inv(7)(q11.22;q35)) (Appendix A).
Based on the AutismDiagnostic Interview-Revised (ADI-R),
the index case met ‘‘broad spectrum’’ criteria according to
the Autism Genetics Research Exchange (AGRE) pheno-
type algorithm (Appendix A) but did not meet the full cri-
teria for ASD according to the combination of ADI-R and
Autism Diagnostic Observations Scales (ADOS). We map-
ped the chromosomal rearrangement by using ﬂuorescent
in situ hybridization as described14 and found that the in-
version breakpoints disrupted the genes AUTS2 at 7q11.22
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Figure 1. Mapping of a De Novo Inversion (inv(7)(q11.22;q35)) in a Child with Developmental Delay
(A) Pedigree of a family with an affected male child with developmental delay. The parents, grandparents, and two older siblings are not
affected with a neurodevelopmental disorder.
(B) G-banded metaphase chromosomes and ideogram for normal (left) and inverted (right) chromosomes are presented.
(C and D) FISH mapping of q35 (C) and q11.22 (D) breakpoints. Images show the two BACs that span the breaks. The experimental probe is
seen at the expected positions on the normal (nml) chromosomes 7q35 and 7q11.22, respectively. Two fluorescence signals are visible on
the inverted (inv) chromosomes indicating that the probes span the break points. Photographs were taken with a 1003 objective lens.
(E and F) Schematics showing the location of the spanning BACs relative to the disrupted genes.
(E) The edges of the BAC RP11-1012D24 are 1314 kb and 821 kb away from the centromeric and telomeric ends of CNTNAP2.
(F) The edges of the BAC RP11-709J20 are 926 kb and 110 kb away from the centromeric and telomeric ends of AUTS2.genomic region of 7q11.22; BAC RP11-709J20 spans the
inversion and is within intron 5, placing the break be-
tween exons 5 and 6. CNTNAP2maps to a 2.3 MB genomic
region on 7q35; BAC RP11-1012D24 was found to span the
inversion and includes coding exons 11 and 12, placing
the break between exons 10 and 13. We further evaluated
the patient by performing array-based competitive geno-
mic hybridization with a chromosome 7-speciﬁc micro-
array containing approximately 385,000 probes with an
average spacing of 400 base pairs (Nimblegen). No large-
scale deletions or duplication were observed within several
megabases of the breakpoints.
Both genes, either alone or in combination, represent
strong candidates for contributing to the etiology of the166 The American Journal of Human Genetics 82, 165–173, Januarycognitive and social delays seen in the index case. AUTS2
encodes a predicted protein of unknown function that
was originally identiﬁed through mapping of a chromo-
somal abnormality in a pair of twins with ASD.15 Addition-
ally, three cases of MR and balanced translocations of
AUTS2 have been reported recently.16 However, a copy
number polymorphism in unaffected individuals has also
been reported at the AUTS2 locus,17 suggesting that hap-
loinsufﬁciency and structural rearrangements at this in-
terval may be tolerated in some cases. We evaluated the
expression of AUTS2 mRNA by RT-PCR in peripheral lym-
phoblasts from the patient as well as unaffected family
members; the patient’s expression levels were normal for
exons 50 to the break, but reduced by approximately 50%2008
Figure 2. Expression of Cntnap2 mRNA in Postnatal Mouse Brain
Sections of P9 mouse brain were hybridized with a Cntnap2 antisense probe. We detected expression in the cortex (A–D), septum (A),
basal ganglia (A and B), many thalamic (B–D) and hypothalamic (C–E) nuclei, with particularly high levels observed in the anterior nu-
cleus and the habenula, part of the amygdala (C), the superior colliculus and the periaqueductal gray (F), pons, cerebellum, and medulla,
again with particularly high levels seen in the inferior olive. All panels represent coronal sections and are shown in anterior to posterior
order. Ctx, cortex; CPu, caudate putamen; Se, septum; GP, globus pallidus; Th, thalamus; Hip; hippocampal formation; A, amygdala; HTh,
hypothalamus; SC, superior colliculus; PAG, periaqueductal gray; Pn, pontine nuclei.for exons distal to it (data not shown). Results of rese-
quencing of this gene will be described in a separate paper.
CNTNAP2 is also a strong candidate for involvement in
social and cognitive delay. It is a neuronal cell adhesion
molecule known to interact with Contactin 2 (Cntn2),
also known as TAG-1, at the juxtaparanodal region at the
nodes of Ranvier, which are the regularly spaced gaps
between the myelin-producing Schwann cells in the
peripheral nervous system (PNS).18,19Whereas previous in-
vestigations have largely focused on the role of CNTNAP2
in PNS development, a recent report demonstrated that
a homozygous CNTNAP2 mutation in the Old Order Am-
ish population results in intractable seizures, histologically
conﬁrmed cortical neuronal migration abnormalities, MR,
and ASD.3 These data, along with our earlier identiﬁcation
of a cytogenetic disruption of CNTN4 in a child with MR
and ASD,2 suggests the possible involvement of a Contac-
tin-related pathway in these disorders.
As was the case with AUTS2, evidence from available
reports of cytogenetic abnormalities involving CNTNAP2
has been inconsistent. In one instance, Tourette syndrome
and developmental delay were identiﬁed in a family carry-
ing a complex rearrangement disrupting CNTNAP2.20
More recently, carriers of a balanced t(7;15) translocation
involving the coding region of CNTNAP2 were described
as normal.21
Given the absence of expression of CNTNAP2 in periph-
eral lymphoblasts, we were not able to directly evaluate
expression changes in our index case. However, our char-
acterization of the de novo inversion in the only affected
member of the pedigree, our previous ﬁndings with regardThe Amto CNTN4,2 and the strong evidence that rare homozygous
mutations in CNTNAP2 cause ASD3 supported the hypoth-
esis that this molecule plays a key role in central nervous
system (CNS) development, and autism in particular, and
led us to study the transcript and its protein product.
We examined the distribution of Cntnap2 mRNA in the
mouse and human CNS by using in situ hybridization22
with digoxigenin-11-UTP RNA probes complementary to
bases 3909 to 4890 of the mouse Cntnap2 cDNA
(NM_025771) or to bases 1343 to 2496 of the human
CNTNAP2 cDNA (NM_014141.3). We found widespread
expression in embryonic and postnatal mouse brain in-
cluding within the limbic system (Figures 2 and 3C), a neu-
roanatomical circuit implicated in social behavior. In hu-
man brain, we conﬁrmed previous ﬁndings of CNTNAP2
mRNA in all cortical layers of the temporal lobe (Figure 3).
We also evaluated Cntnap2 protein and its putative
binding partner, Cntn2/TAG-1, in subfractioned postnatal
day 9 rat forebrain lysates.23,24 Both Cntnap2 and Cntn2/
TAG-1 were present in the fraction containing synaptic
plasma membranes, consistent with their forming a physi-
cal complex in this compartment (Figure 3D). These data
localized CNTNAP2 and elements of a Contactin-related
pathway with neuronal structures of marked interest
with regard to autism,8,9,25–29 and prompted us to pursue
an intensive genetic investigation of CNTNAP2 among
individuals with ASD. All experiments were approved by
the Yale University School of Medicine Institutional Ani-
mal Care and Use Committee.
Given our cytogenetic data and the recent ﬁndings of
Strauss et al.,3 we elected to resequence all 24 coding exonserican Journal of Human Genetics 82, 165–173, January 2008 167
Figure 3. Expression and Biochemical
Analyses of CNTNAP2/Cntnap2
(A–C) Cortical expression of CNTNAP2/
Cntnap2. Sections of human temporal cor-
tex at 6 and 58 years of age (A and B)
and P7 mouse cortex (C) were hybridized
with corresponding antisense riboprobes.
Expression is detected in cortical layers
II–V in the human temporal lobe (A and
B) and II–VI in the mouse neocortex (C).
(D) Cofractionation of Cntn2/TAG-1 and
Cntnap2 in synaptic plasma membranes.
Rat forebrain homogenate (homog.) was
subfractionated into postnuclear superna-
tant (S1), synaptosomal supernatant (S2),
crude synaptosomes (P2), synaptosomal
membranes (LP1), crude synaptic vesicles
(LP2), synaptic plasma membranes (SPM),
and mitochondria (mito.). The synaptic
membrane protein N-cadherin and the syn-
aptic vesicle protein synaptotagmin 1
served as markers for these respective frac-
tions. Numbers on the left indicate posi-
tions of molecular weight markers. Protein
concentrations were determined with the Pierce BCA assay and equal amounts of each fraction were analyzed. Monoclonal antibodies to
Cntn2/TAG-1 (3.1C12, developed by Thomas Jessell, Columbia University) were obtained from the Developmental Studies Hybridoma Bank
maintained by the University of Iowa, to synaptotagmin 1 (41.1) from Synaptic Systems (Go¨ttingen, Germany), and to N-cadherin from BD
Biosciences (# 610920). Polyclonal antibodies to Cntnap2 were obtained from Sigma (# C 8737).of CNTNAP2 (Table 1) in 635 affected individuals and 942
uncharacterized controls. This approach was selected be-
cause it is robust in the face of allelic heterogeneity and
has proven valuable in identifying rare causal mutations168 The American Journal of Human Genetics 82, 165–173, Januaryin idiopathic autism.8,9 Moreover, in other complex
genetic disorders, heterozygote nonsynonymous variants
found in genes contributing to rare recessive diseases have
been shown to confer risks in the broader population.30Table 1. Primer Sequences for Mutation Screening of CNTNAP2
Exon Numbera Forward Primer Reverse Primer Product Size (bp)
1 CACACAGTGCAAGAGGCAATAC GATGCACTTCGGAGTTGATACC 420
2 TTAACCAACACATACCAATCGTT GATTTCTGGTGTCTGCCAACAT 298
3 GAAATAGAGCACTGCCAAGACC CATTGGATAGAAATTACAGCCTGA 481
4 ACCATTGGATGACATTTGTGTT GGTAGTTTATTGTCAGAGAAAGCAA 355
5 CATTTATTCTTTGCAGACACCTG TTTAAAGAATTGAGCAACATGAACA 368
6 TATCCCAGGTTAACTCGAATGG TCAGGTTTTTAAAATTGTCAGTGTC 466
7 ATTTTGGAGGCAGAATGCTATAA TTTTGCCCAAACACAAATATGAT 400
8 AGGCTGTGCTTCAAAACTTGTA GTAACACCAGCAAAACCAAACA 458
9 AAATCGTGATTTGTTGATTTTGG TTTTTGTTTTGCTCAGTGGAATTA 382
10 GTAGTTGGATGTGATGGCTGTG TGGTAATTTCCACCTTACCTGTTT 399
11 ATATATTGCCCAGACAGCTTGG TTGGTTTTTCAGATTCGAGTGA 318
12 GGTTTGCTAGCATTGCAATATG GAAACAAACCATTGGTGGAACT 292
13 AACACTGTTCTACACCAGCTCAG TCTTAGCTTCATTCCCCAGAAA 496
14 TCAGAGTATTCCTGGGGAAGTG TTTGTCAGTTGGGTTAGTTCCA 391
15 TGCTATGAGACCACCTATGGAA AGTCTGATTGCAGGCATCTTCT 390
16 GAGGATTTGGTCCAATGTTGTT GGCTTGTGTGTCCACCTCTAGT 465
17 ATTTTGCCATCGACCTTTGTAG TGTGCAGGCTCTTAAAAATCAAC 468
18 CTATGCAGTGTCATCTCCTACCAC TTGGAAAATTCCTACCTAAGTTGA 488
19 ACTTACTCAGATGCCCTTCCTG TGGCAAGTTGTTTTCCTGATATT 539
20 GACATCAAGGGAGGGAGTAAAG CTATCCCCTCAAAACAAAACCA 667
21 GGTGTTTTAGAGTCAGTGCTGATG AGAACAACCACGTAACTTTCCTGT 381
22 TGCAGCCCTAAATCTTATCGAC CCTGAGAACTCCGTACTCACAA 560
23 CTGTTGTGATTCTTGTGGGAGA CAGCAAAATGAATAATGTAAAAACC 367
24 CTGACGGAGCTGTAGTGAAGTG CACGGGTCTTTAGAACACCTCTA 611
a As defined by NM_014141.2008
DNA was ampliﬁed with a standard polymerase chain
reaction (PCR) over 35 cycles with a 56.7C annealing tem-
perature31 and analyzed with Sequencher (Genecodes) or
PolyPhred software after dye terminating sequencing on
one strand. Use of human subjects was approved and per-
formed in accordance with the Yale University School of
Medicine Human Investigation Committee. The Institu-
tional Review Board at the University of Pennsylvania
School of Medicine provides human subjects protection
and oversight for AGRE.
We evaluated both cases and controls in the identical
fashion in search of rare nonsynonymous, frame-shift,
nonsense, and splice-site variants. Those changes that
were found only in the case or the control group in the ini-
tial sequencing effort were further genotyped with Custom
Taqman Genotyping assays (Applied Biosystems) in an
additional control sample of 1073 unrelated white sub-
jects. Variants with allele frequencies greater than 1/4000
in the combined control sample were excluded (data avail-
able on request). One variant, R283C, which was found
once among the sequenced controls, failed further geno-
typing but was included in subsequent analyses. All rare
nonsynonymous variants were examined for conservation
across diverse species with a ClustalW alignment to the
top full-length BLASTp hits of each species (Table 2;
see Figure S1 available online). Additionally, substitutions
were examined by the amino acid analysis programs Poly-
Phen and SIFT (protein submission option), with Q9UHC6
as the reference CNTNAP2 protein, to identify those pre-
dicted to be possibly or probably deleterious to protein
function (Table 2).
The case group was comprised of affected children from
584 families that were obtained from the Autism Genetics
Research Exchange (AGRE) and 51 affected children re-
cruited at the Yale Child Study Center. Diagnoses included
96.7% autism, 2.0% broad spectrum, and 1.3% not quite
autism (see AGRE diagnosis in Web Resources). Males
accounted for 81.1% of the sample. The ethnic/racial
composition of the group was 587 white (92.4%), 24
white-Hispanic (3.8%), 7 unknown (1.1%), 6 Asian
(0.9%), 6 more than one race (0.9%), 3 black or African-
American (0.5%), 1 Native Hawaiian or Paciﬁc Islander-
Hispanic (0.2%), and 1 more than one race-Hispanic
(0.2%). The resequenced control group consisted of 942
individuals: 757 white (80.4%), 94 white-Hispanic (10%),
and 91 Asian (9.6%). These individuals were not evaluated
for developmental delay or autism and were drawn from
studies of renal disease, myocardial infarction, or normal
human variation panels.
We found a total of 27 nonsynonymous variants among
635 cases, 13 of which had an allele frequency of less than
1/4000 (Figure 4; Table 2). Of these 13 rare variants, 8 were
predicted to be deleterious or were found at regions con-
served across all species examined (Figure S1; Figure 4A).
In four cases, these potentially deleterious alleles were
identiﬁed in pedigrees with more than one affected indi-
vidual and three of these showed segregation with ASDThe Amin the affected ﬁrst-degree relatives (Figure 4B). Among
the 942 controls, 35 nonsynonymous variants were identi-
ﬁed; 11 of these were rare and 6 were predicted to be delete-
riousorwere conservedacross all species (Figure S1;Table2).
Although the rates of all unique and predicted deleteri-
ous/conserved variants were, respectively, 1.75- and 2-
fold higher in cases compared to controls, neithermet a sta-
tistical threshold for an association of increased mutation
burden with ASD (Fisher exact test p ¼ 0.21, OR 1.76
95% CI: 0.80-3.87; p ¼ 0.27, OR 1.98 95% CI: 0.72-5.49).
One highly conserved variant, I869T, which was
predicted to be deleterious by SIFT, was identiﬁed in four
affected individuals from three unrelated families with au-
tism but was not present in 4010 control chromosomes,
supporting an association for this substitution (Fisher
exact test; p ¼ 0.014). In each family, the variant was in-
herited from an apparently unaffected parent. Its absence
among several thousand control chromosomes, its conser-
vation across species, and its segregation with affected
Table 2. Unique Nonsynonymous Variants Identified in ASD
Cases and Controls
Varianta Race/Ethnicity Predicted Deleteriousb Conservedc
ASD (n ¼ 635)
N407Sd white N N
N418D white-Hispanic N N
Y716C white N N
G731Se,f more than one (Asian)f N Y
I869Te white Y, S Y
I869Td,e white Y, S Y
I869Te white Y, S Y
R906H white N N
R1119He white Y, P&S Y
D1129He white-Hispanic Y, P&S Y
A1227T white N N
I1253Te white-Hispanic Y, S N
T1278Ie white Y, P&S N
Controls (n ¼ 942)
R114Q white-Hispanic N N
T218Me white Y, P&S Y
L226Me white Y, S Y
R283Ce,g white Y, P&S Y
S382Ne white-Hispanic Y, S Y
E680Ke white Y, P&S Y
P699Qe white-Hispanic N Y
G779D Asian N N
D1038N white N N
V1102A white N N
S1114G white N N
a Amino acid changes found only in cases (top of table) or only in controls
(bottom of table).
b P, PolyPhen; S, SIFT.
c Amino acids were considered conserved if all sequences were identical or
only conserved substitutions were seen.
d N407S/I869T were found in one proband on opposite chromosomes.
e Variants predicted to be deleterious or conserved.
f Parental DNA was sequenced and the suspect variant was determined to
derive from the father who was Asian.
g Variant failed genotyping.erican Journal of Human Genetics 82, 165–173, January 2008 169
Figure 4. Sequencing of CNTNAP2 Identifies Rare Unique Nonsynonymous Variants
(A) Diagram of the CNTNAP2 protein highlighting the location of unique predicted deleterious variants (modified from SMART). The
locations of patient variants are indicated. Variants in red are predicted to be deleterious or at conserved sites. Asterisk indicates variant
was identified in three independent families; SP, signal peptide; FA58C, coagulation factor 5/8 C-terminal domain; LamG, Laminin G
domain; EGF and EFG-L, epidermal growth factor-like domains; TM, transmembrane domain; 4.1M, putative band 4.1 homologs’ binding
motif; black vertical bar, C-terminal type II PDZ binding sequence. Figure is to scale.
(B) Pedigrees for all families with variants predicted to be deleterious at conserved sites (I to XIII) or which all affected relatives carry the
identified variant (IX–X). The individuals carrying the suspect allele are noted and are heterozygous. The brothers inheriting the D1129H
variant are monozygotic twins. Affected status was calculated with the AGRE diagnosis algorithm, which is based on ADI-R scores. Black-
ened symbols represent an autism diagnosis, half-filled symbols indicate a not-quite-autism (NQA) diagnosis, and crosshatched individ-
uals have a broad spectrum diagnosis.status among ﬁrst-degree relatives (Figure 4B) all suggest
that this variant warrants further attention. However, in
light of the low observed allele frequency, it is not possible
to rule out false positive results because of cryptic popula-
tion stratiﬁcation, despite the fact that the variant was
found only among white families, the ethnic group that
also represented the vast majority of controls.
When viewed in the context of two independent stud-
ies demonstrating linkage and/or association of common170 The American Journal of Human Genetics 82, 165–173, JanuarySNPs near CNTNAP2 with ASD,4,5 our results both lend
support to these ﬁndings and demonstrate the bounds of
the potential contribution of rare variants in this tran-
script. Our conﬁrmation of the expression of CNTNAP2
in brain regions considered relevant in ASD as well as the
demonstration of CNTNAP2 protein and its binding part-
ner in the synaptic membrane support the biological plau-
sibility of these ﬁndings, particularly given the identiﬁca-
tion of ASD-related mutations in other synaptic proteins2008
including Neuroligin 3, Neuroligin 4 X-linked, SHANK3,
and Neurexin 1.8,9,28,29 The ﬁnding of a disrupted
CNTNAP2 transcript resulting from a de novo chromo-
somal abnormality, the identiﬁcation of multiple, rare,
highly conserved variants in the case group that were not
present in controls, and the association of I869T with ASD
all suggest that some rare variants that disrupt protein func-
tionmay contribute to disease risk. However, the absence of
a statistically signiﬁcant burden of rare or highly conserved
mutations in cases versus controls suggests that the risk for
an ASD diagnosis resulting from rare heterozygote coding
changes is not likely to be large, because our sample was
well powered to identify an odds ratio of 3.5 or greater
(log-additive case-control design, QUANTO v.1.1).
Given the recent spate of whole-genome association
studies in complex disorders demonstrating that common
disease alleles may confer much smaller risks than previ-
ously anticipated,32,33 it is plausible that alleles conferring
risks lower than 3.5 might still be subject to considerable
negative selection, particularly in the case of ASD given
its early onset and pathognomonic impairment in social
interaction. A much larger case-control mutation burden
analysis would be needed to answer this important ques-
tion. Moreover, if investigations of other complex disor-
ders serve as a model,30 evaluation of the relationship
between heterozygote coding variants and quantitative
traits may provemore informative than relying on categor-
ical diagnoses. Again, based on the low frequency of highly
conserved nonsynonymous changes in CNTNAP2, a mark-
edly larger sample would be required to support such an
analysis. Of course, it is also possible that as a deeper
understanding of the mechanism by which homozygous
mutations lead to neuronal migration abnormalities and
ASD is attained, the ability to better distinguish truly dele-
terious heterozygote variants from neutral substitutions
will increase the power of the type of case-control muta-
tion burden analyses presented here.
At present, data from two common variant studies,4,5
parametric linkage analysis in an isolated population,3 as
well as the molecular cytogenetic, expression, biochemi-
cal, and resequencing studies presented here suggest that
further study of both common and rare variation in
CNTNAP2 is needed and may lead to a better understand-
ing of the genetic etiology and molecular mechanisms of
autism and related neurodevelopmental disorders.
Appendix A
Clinical Description of the (46,XY,inv(7)(q11.22;q35))
Patient
The patient is a 4.5-year-oldmalewhowas born at 38weeks
of gestation to his 33-year-old G3P3 mother by Caesarian
section because of breech position. Birth weight was 3.3 kg.
His neonatal course and infancy were complicated by
poor feeding and severe gastresophageal reﬂux (conﬁrmed
by KUB/UGI at 2.5 months) in the context of global hypo-The Amtonia. This eventually led to PEG tube placement at
6 months of age. Weight at 7 weeks was 4.4 kg (10th–25th
percentile). Genetic evaluation and testing at 3 months of
age, in addition to a karyotype, included a normal FISH
study for the Prader-Willi locus (SNRPN probe, 15q11.2),
performed because of signiﬁcant hypotonia. Antiviral anti-
body titers for toxoplasma, herpes simplex, and cytomega-
lovirus were negative at 2.5months. Rubella IgGwas 1.1 (at
lower limit of immune range). Serum glucose and electro-
lyteswere normal, with bicarbonate of 21mEq/L and anion
gap of 11. Urinalysis was normal, with no ketones. Lactic
acid, at 3months of age, was 1.4 (range 0.5–2.2) and ammo-
nia was 63 (range 28–80). Creatine kinase level was 106
(normal range 0–200 IU/L). Hepatic transaminase values
were within normal limits. Plasma amino acid and acylcar-
nitine analyses, and urine acylglycine and organic acid pro-
ﬁles, were normal. Transferrin isoelectric focusing to rule
out carbohydrate-deﬁcient glycoprotein syndromes was
normal, as was plasma 7 dehydrocholesterol determina-
tion, to rule out Smith-Lemli-Opitz Syndrome. Cerebrospi-
nal ﬂuid amino acids, lactate, and pyruvate were normal.
Ophthalmological evaluation at 3.5 months was initiated
for a history of visual inattention during early infancy. Elec-
tro-retinogram and Preferential Looking Test of Visual Acu-
ity were normal for age. Echocardiogram was normal at 7
months of age. Brain MRI at 2.5 months showed delayed
myelination (lack of myelin within the anterior limb of
the internal capsule, but normal myelination within the
perirolandic white matter and posterior limbs of the inter-
nal capsules). In addition, there was a prominent subarach-
noid space bifrontally with prominent ventricular system
consistent with hypotrophy of the frontal and temporal
lobes. EEG was normal.
Clinical genetic evaluation at 3.5 years revealed a past
medical history signiﬁcant for reﬂux in the ﬁrst year of
life, three previous episodes of pneumonia, hypotonia,
tight heel cords, strabismus repair, and left inguinal hernia
repair. He had pressure-equalizing tubes inserted into both
ears for recurrent otitis media with conductive hearing
loss. Family history was signiﬁcant for two normally devel-
oping older siblings, and no history of cognitive or motor
delays in an extended 3-generation pedigree. On physical
examination, height was 100.2 cm (75th–90th percentile),
weight was 14.7 kg (25th–50th percentile), and occipito-
frontal head circumference was 49.4 cm (25th–50th percen-
tile). Facies were essentially nondysmorphic except for
surgically corrected strabismus and downslanting palpe-
bral ﬁssures. Distinctive physical ﬁndings included mild
bilateral 5th digit clinodactyly, 2–3 toe syndactyly (not
Y-shaped), genu and pes valgus, persistent fetal pads on
toes, tight Achille’s tendons, and prominent scrotal raphe.
Measurements of ocular distances, hands, feet, inter-nipple
distance, and stretched penile length were within normal
limits. No genetic syndrome was recognizable by his clini-
cal geneticist (T.M.M.).
Developmentally, the patient did not smile socially until
after 3 months, crawled at 13.5 months, walked and saiderican Journal of Human Genetics 82, 165–173, January 2008 171
his ﬁrst word at 24 months, and began constructing 2-
word phrases at 3 years of age. The Bayley Scales of Infant
Development showed that the child was in the ‘‘signiﬁ-
cantly delayed’’ range. On the Vineland-II, a parent report
instrument, the patient had the following standard scores
(the mean for each test is 100 with a standard deviation of
15): communication, 67; daily living skills, 77; socializa-
tion, 77; motor, 64; and adaptive behavior composite, 68.
Tests of ﬁne motor skills with the Peabody Developmental
Motor Scales-2 (PDMS-2) placed him 2 SD below the mean.
The patient was evaluated with the ADI-R and ADOS at
the Yale Child Study Center at 49 months of age. On
ADI-R, the parents reported an age at ﬁrst word of 30
month and at ﬁrst phrase of 48 months, which differs
slightly from the documented medical history. Addition-
ally, the parents reported that the patient had a ‘‘history
of attacks that might be epileptic.’’ These, as noted, were
followed up by a pediatrician with an EEG, which was nor-
mal. The patient met ADI-R scoring criteria for social (10),
behavior (4), and age of onset (4). The patient did not meet
cutoffs on the communication domains: verbal (0) or non-
verbal (3). Based on the ADI-R algorithm used by AGRE
repository (from which the mutation screening sample
was derived), the patient would be classiﬁed as ‘‘Broad
Spectrum.’’ However, the patient did not meet the ADOS
criteria for a diagnosis of ASD.
Supplemental Data
One supplemental ﬁgure can be found with this article online at
http://www.ajhg.org/cgi/content/full/82/1/165/DC1/.
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